Motor disorder

XEOMIN® (incobotulinumtoxinA) receives three new therapeutic indications in Australia

Retrieved on: 
Wednesday, November 22, 2023
Health, Consumer, Neurology, Children, Pharmaceutical, Biotechnology, Disease, Physician, Drooling, Brain, Nerve, Hope, Spasticity, Therapy, Pneumonia, Incidence, Neurotoxin, Choking, Social isolation, Risk, UMN, TGA, Spasm, Patient, Therapeutic Goods Administration, Stroke, Dehydration, Rehabilitation, Trial of the century, Motor disorder, Survivor, Disability, Saliva, Cerebral palsy, Skin, CP, Dietary supplement, Hypersalivation

This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market.

Key Points: 
  • This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market.
  • Additionally, XEOMIN ® is now approved for the treatment of pediatric spasticity of the upper and lower limb in children.
  • Until recently, only oral medications were approved for the treatment of sialorrhea, and these were associated with a number of systemic side effects.
  • The degree of disability may however differ among individuals, depending on symptoms intensity, number of involved body parts, and concomitant disorders.

New Research in the Treatment of Parkinson's Disease

Retrieved on: 
Wednesday, December 6, 2023
Parkinson's disease, B cell, Gait, Brain, Research, Alzheimer's disease, Ageing, Freezing, Glioblastoma, PD, Tremor, Patient, Humanized mouse, Nervous system, Wound healing, Heart failure, University, Movement, Ceramic, Burnett School of Medicine, Biomedical sciences, Cognition, UCF, Neurodegenerative disease, Motor disorder, Human, COM, Neurology, Rat, Rigidity, Pharmaceutical industry, Medicine, Disease

The UCF researchers had previously published a study demonstrating that they could increase wound healing using this treatment.

Key Points: 
  • The UCF researchers had previously published a study demonstrating that they could increase wound healing using this treatment.
  • Parkinson's disease is the most frequent motor disorder and the second most frequent neurodegenerative disease after Alzheimer's Disease (AD).
  • The tremor, rigidity, and slowness of movement associated with Parkinson's disease affect up to 10 million people throughout the world.
  • The UCF research team is conducting ongoing research on the use of the Gladiator ceramic blanket in animal models of Alzheimer's disease, Parkinson's disease, traumatic brain injury, and heart failure.

We got the beat: How we perceive rhythm involves neurological processes that control movement

Retrieved on: 
Sunday, October 1, 2023
Music, Stuttering, Human, Firefly, Speech, Culture, Kálmán, Perception, Finger, DSM-IV codes, Brain, Research, Movement, Cerebral cortex, MRI, Walking, Time, Hearing, Sound, Basal ganglia, Motor disorder, Nightclub, Medical imaging, Instrumentation

Whether or not you’re a musician, somehow you know intuitively when to speed up or slow down to stay in time.

Key Points: 
  • Whether or not you’re a musician, somehow you know intuitively when to speed up or slow down to stay in time.
  • A wide range of living and non-living systems show synchronization, the tendency to coordinate rhythmic activity across interconnected groups.
  • And as a scientist, I am fascinated by the processes in the mind and brain that allow us to interact so expertly and spontaneously with rhythm.

Rhythm and the brain

    • But it appears that even our ability to mentally follow and anticipate musical rhythms is tied up with the brain processes we use to move our bodies.
    • Using functional MRI, music neuroscientists have established that actively listening to rhythm activates the supplementary motor area of the cerebral cortex and the basal ganglia in the deep brain, both of which are important for generating voluntary movements.
    • Anticipating and processing events in a rhythm may draw on the same brain mechanisms as anticipating and processing the sensory consequences of our own movements.

Causes of motor disorders

    • Drawing links between motor control and rhythm perception may help us make sense of the underlying causes of neurological disorders that both affect rhythm perception and benefit from rhythm-focused therapies, including Parkinson’s, Huntington’s, and stuttering.
    • Developmental stuttering (a stutter during speech that arises in early childhood) is associated with impairment in rhythm perception and weaker ability to tap in time with a metronome.

Rhythm and boundaries

    • I believe that how we sense rhythm blurs the boundaries between our internal and external worlds.
    • As we play music in a group, we literally lose ourselves in the rhythm: we no longer predict the timing of our own sounds separately from the mix, but instead predict the timing of all sounds based on the group’s rhythm as a whole.

Prediction and action

    • I suspect that the last ingredient is the tight relationship between prediction and action.
    • According to one exciting theory of the neural control of action, we move our bodies not by sending “commands” to them, but instead by predicting what we will experience when we move them.
    • A shared rhythmic experience is a fluid interplay between sound, external expectations, self-expectation and action.

Meijer Celebrates Conductive Learning Center of North America's 25th Anniversary with Donation to Expand Programming and Scholarship Opportunities

Retrieved on: 
Tuesday, September 12, 2023
Disability studies, CE, Central nervous system, Education, Electrical conductor, CLC, Brain, Movement, Organization, Student, Cerebral palsy, Child, Place of birth, Diagnosis, Motor disorder, Nursing, Meijer

GRAND RAPIDS, Mich., Sept. 12, 2023 /PRNewswire/ -- As part of its ongoing commitment to support its communities, Meijer announced today it's helping the Conductive Learning Center (CLC) of North America expand on existing programming and scholarship opportunities, as well as construct a new on-site playground.

Key Points: 
  • The CLC serves individuals with motor disorders related to complications of premature birth, Cerebral Palsy, Spina Bifida, or brain injury.
  • The vision of CLC is that every child living with a motor disability has the tools and education needed to be healthy, confident, self-reliant, and achieve a joy-filled and rewarding life.
  • "At Meijer, we're committed to helping families in the communities we serve," said Rick Keyes, Meijer President & CEO.
  • "We believe every person should have the opportunity to live a healthy, confident and rewarding life, and organizations like the Conductive Learning Center help make that happen every day."

Netflix' "Take Care of Maya" Brought the Disease CRPS Into Public Awareness, Now Parents Are Asking if They or Their Children Have It

Retrieved on: 
Friday, July 14, 2023
Complex regional pain syndrome, Clothing, Foot, Weakness, Dystonia, Maya, CRPS, Multimedia, Temperature, Persistent, Movement, Paralysis, Pain, Motion, Political moderate, System, Skin temperature, Trauma, Netflix, News, Pediatrics, Motor disorder, Nursing, Online shopping

MILFORD, Conn., July 14, 2023 /PRNewswire/ -- CRPS, or Complex Regional Pain Syndrome, is a serious, incurable disease that may not be as rare as it is rarely diagnosed. The good news is that if it is diagnosed early, it can be put into remission, often for a lifetime. RSDSA, the international CRPS support group, shows you how to tell if you or a loved one may have CRPS and where to get the right help. Just follow this link to find out if You or Your Child Has CRPS.

Key Points: 
  • Here is how to self-diagnose the signs of CRPS and where to look for the right medical help.
  • MILFORD, Conn., July 14, 2023 /PRNewswire/ -- CRPS, or Complex Regional Pain Syndrome, is a serious, incurable disease that may not be as rare as it is rarely diagnosed.
  • The good news is that if it is diagnosed early, it can be put into remission, often for a lifetime.
  • The Netflix documentary "Take Care of Maya" has raised awareness of, and many questions about CRPS.

Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction

Retrieved on: 
Wednesday, May 17, 2023
University College London, Gene, AAV, Advisory board, Microfluidics, Protein, Patient, Vivisection, Nervous system, Cell, B cell, Therapy, UK, Neurology, Motor disorder, Eurosport 1, Society, Dietary supplement, 3D printing, Mobile phone

LONDON, UK & NEW YORK, USA – 17 May 2023, Sania Therapeutics (the “Company”), focused on developing genetic medicines for neural circuit dysfunction, launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.

Key Points: 
  • LONDON, UK & NEW YORK, USA – 17 May 2023, Sania Therapeutics (the “Company”), focused on developing genetic medicines for neural circuit dysfunction, launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.
  • This permits breakthrough efficacy by correcting dysfunctional neural excitation, thereby unlocking a broad range of diseases both within and beyond neurology.
  • “We formed Sania with a simple yet powerful vision: to be the first in developing medicines that treat disorders of neural circuits selectively.
  • Today we are excited to demonstrate proof-of-principle data and unveil our platforms,” said Andy Murray, Ph.D, CEO & Co-Founder of Sania Therapeutics.

Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction

Retrieved on: 
Wednesday, May 17, 2023
University College London, Gene, AAV, Advisory board, Microfluidics, Protein, Patient, Vivisection, Nervous system, Cell, B cell, Therapy, UK, Neurology, Motor disorder, Eurosport 1, Society, Dietary supplement, 3D printing, Mobile phone

LONDON, UK & NEW YORK, USA – 17 May 2023, Sania Therapeutics (the “Company”), focused on developing genetic medicines for neural circuit dysfunction, launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.

Key Points: 
  • LONDON, UK & NEW YORK, USA – 17 May 2023, Sania Therapeutics (the “Company”), focused on developing genetic medicines for neural circuit dysfunction, launches today by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.
  • This permits breakthrough efficacy by correcting dysfunctional neural excitation, thereby unlocking a broad range of diseases both within and beyond neurology.
  • “We formed Sania with a simple yet powerful vision: to be the first in developing medicines that treat disorders of neural circuits selectively.
  • Today we are excited to demonstrate proof-of-principle data and unveil our platforms,” said Andy Murray, Ph.D, CEO & Co-Founder of Sania Therapeutics.

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease

Retrieved on: 
Tuesday, May 2, 2023
Diamond, Patent, Priority review, Communication, Motor disorder, CSE, Depression, Dyskinesia, New Drug Application, NDA, Accelerated approval (FDA), USD, NDMA, White Light Rock & Roll Review, Trial of the century, Movement, Pain, Hypertension, Plasma protein binding, Ketamine, Patient, Collection, Phase, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Levodopa-induced dyskinesia, LID, Food, Safety, Pharmaceutical industry

Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.

Key Points: 
  • Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially better than available therapy.
  • NDA review usually does not begin until the drug company has submitted the entire application to the FDA.
  • Summary results of the Phase I/II clinical study:
    Enrolled subjects with moderate to advanced Parkinson’s disease with a target infusion rate being 0.30 mg/kg/hr.
  • Parkinson’s disease is a debilitating disorder that affects an estimated 1 million people in the U.S. and 10 million people worldwide.

PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease

Retrieved on: 
Wednesday, March 29, 2023
Diamond, Patent, Motor disorder, CSE, Depression, Dyskinesia, Marketing, Fast Track, Type, USD, NDMA, Movement, Trial of the century, Pain, Hypertension, Ketamine, Patient, Risk, Phase, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Levodopa-induced dyskinesia, LID, Food, Safety, Pharmaceutical industry, Medical imaging, Risk management

The Company will provide updates to its clinical development initiatives as they arise.

Key Points: 
  • The Company will provide updates to its clinical development initiatives as they arise.
  • Summary results of the Phase I/II clinical study:
    Enrolled subjects with moderate to advanced Parkinson’s disease with a target infusion rate being 0.30 mg/kg/hr.
  • The maximum tolerated infusion rate ranged from 0.20-0.30 mg/kg/hr, which was dependent on either discomfort due to dissociation or hypertension.
  • Parkinson’s disease is a debilitating disorder that affects an estimated 1 million people in the U.S. and 10 million people worldwide.

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

Retrieved on: 
Wednesday, February 1, 2023
Diamond, Ketamine, Food, Safety, Fast track (FDA), Fast Track, Trial of the century, Pain, Type, Motor disorder, LID, Accelerated approval (FDA), Depression, Patient, NDMA, Collection, CSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Patent, Movement, Hypertension, Levodopa-induced dyskinesia, Dyskinesia, USD, Priority review, Pharmaceutical industry, Bookkeeping

In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™.

Key Points: 
  • In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™.
  • The goal date for the FDA in providing its written responses is March 20, 2023.
  • Summary results of the study:
    Enrolled subjects with moderate to advanced Parkinson’s disease with a target infusion rate being 0.30 mg/kg/hr.
  • Clinical programs conducted under Fast Track Designation may be eligible for Accelerated Approval and Priority Review of new drug applications if relevant criteria are met.